

- 1 **Title: Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for**
- 2 **COVID-19 Adjuvanted with AS03**
- 3
- 4 **Supplementary Appendix**

5 *List of investigators*

Country	Investigator	Institution
Argentina	Chirino Navarta, Daniel	Mautalen Salud e Investigación (Expertia SA), Buenos Aires
Argentina	Llapur, Conrado	Clinica Mayo de UMCB SRL, San Miguel de Tucumán
Argentina	Maulen, Sergio	Fundación FunDaMos, Buenos Aires
Argentina	Perez Marc, Gonzalo	Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Buenos Aires
Argentina	Polack, Fernando	Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Buenos Aires
Argentina	Riera, Fernando	Sanatorio Allende, Cordoba
Brazil	Diaz, Ricardo	Azidus Brasil Pesquisa e Desenvolvimento Ltda, Valinhos, Sao Paulo
Brazil	Ferrara, Luciana	Azidus Brasil Pesquisa e Desenvolvimento Ltda, Valinhos, Sao Paulo
Brazil	Freire, Antonio	Santa Casa De Misericordia De Belo Horizonte, Belo Horizonte, Minas Gerais
Brazil	Hammes, Luciano	Centro de Pesquisa Clinica - Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul
Brazil	Itinose, Kengi	Unidade Hospital do Rocio, Campo Largo
Brazil	Nogueira, Mauricio	Fundação Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto
Brazil	Vasconcellos, Eduardo Freire	Instituto de Pesquisas Clinicas L2IP, Brasilia, DF
Brazil	Wolff, Priscila Geller	IBPClin Instituto Brasil de Pesquisa Clinica, Rio de Janeiro
Canada	Abitbol, Alexander	LMC Clinical Research Inc. (CPU), Toronto, Ontario
Canada	Aggarwal, Naresh	Aggarwal and Associates Ltd, Brampton, Ontario
Canada	Badenhorst, Josias	CARe Clinic, Red Deer, Alberta
Canada	Dionne, Marc	CHU de Québec-Université Laval, Quebec City, Quebec
Canada	Frechette, Andre	Diex Research Quebec Inc, Quebec City, Quebec
Canada	Gauthier, Jean Sebastien	QT Research Sherbrooke, Sherbrooke, Quebec
Canada	Girard, Ginette	Diex Research, Sherbrooke, Quebec
Canada	Henein, Sam	SKDS Research Inc., Newmarket, Ontario
Canada	Libman, Michael	McGill University Health Centre Vaccine Study Centre, Pierrefonds, Quebec
Canada	Paquette, Jean-Sebastien	Diex Recherche Joliette, Saint-Charles-

Country	Investigator	Institution
Canada	Tellier, Guy	Borromée, Quebec Manna Research Mirabel, Mirabel, Quebec
Canada	Vale, Noah	Manna Research Toronto, Toronto, Ontario
Canada	Vallieres, Gerald	Manna Research Quebec, Lévis, Quebec
Canada	Wallace, Garry	Dawson Clinical Research Inc., Guelph, Ontario
Mexico	Castro Melchor, Liliana	Investigación Biomédica para el Desarrollo de Fármacos, S.A. de C.V., Zapopan
Mexico	De los Rios Ibarra, Manuel	Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada SC, Culiacan
Mexico	Del Carpio, Luis	Sociedad de Metabolismo y Corazon S.C (SOMEKO), Veracruz
Mexico	Guzman Romero, Ana Karla	RM Pharma Specialists S.A. de C.V., Ciudad de Mexico
Mexico	Martinez Perez, Jose Miguel	Integra RGH Centro de Investigacion - Clinica de Ozonoterapia RGH AC, Puebla
Mexico	Rios Mejia, Edmundo Daniel	Investigación Biomédica para el Desarrollo de Fármacos, S.A. de C.V., Aguascalientes
Mexico	Sanchez Campos, Efen Alberto	Centro Multidisciplinario para el Desarrollo Especializado de la Investigación Clínica en Yucatan S.C.P. (CEMDEICY S.C.P.), Merida
United Kingdom	Apoola, Ade	University Hospitals Derby and Burton, Derby
United Kingdom	Galloway, James	Kings College Hospital, London
United Kingdom	Healy, Brendan	Public Health Wales NHS Trust, Cardiff
United Kingdom	Kyriakidou, Christina	Synexus Midlands Clinical Research Centre, Birmingham
United Kingdom	Lacey, Charles	University of York/York Teaching Hospital, York
United Kingdom	Moore, Patrick	University Hospitals Dorset NHS Foundation Trust, Bournemouth
United Kingdom	Nicholls, Helen	Synexus Wales Clinical Research Centre DRS, Cardiff
United Kingdom	Prestwell, Carol	Synexus Lancashire Clinical Research Centre DRS, Chorley
United Kingdom	Soiza, Roy	NHS Grampian, Aberdeen
United Kingdom	Viljoen, Marlies	Synexus Manchester Clinical Research Centre DRS, Manchester
United Kingdom	Whittington, Ashley	London North West University Healthcare NHS Trust, Harrow
United States	Aazami, Hessam	Hope Clinical, Canoga Park, California

Country	Investigator	Institution
United States	Adelglass, Jeffrey	Research Your Health, Plano, Texas
United States	Anderson, Duane	Excel Clinical Research, Las Vegas, Nevada
United States	Arora, Samir	Aventiv Research Inc, Columbus, Ohio
United States	Berger, Ira	Meridian Clinical Research, Rockville, Maryland
United States	Bordon, Jose	Ascension Providence Health System, Washington, DC
United States	Bradley, Paul	Meridian Clinical Research, Savannah, Georgia
United States	Carlson, Mark	Be Well Clinical Studies, LLC, Lincoln, Nebraska
United States	Casey, Sherri	Benchmark Research, Covington, Louisiana
United States	Chu, Laurence	Benchmark Research, Austin, Texas
United States	DeFrancisco, Don	Pharmacology Research Institute, Newport Beach, California
United States	Ebuh, Valentine	Global Medical Research, Dallas, Texas
United States	Ensz, David	Meridian Clinical Research, Sioux City, Iowa
United States	Essink, Brandon	Meridian Clinical Research LLC, Omaha, Nebraska
United States	Fiel, Thomas	Fiel Family & Sports Medicine/ CCT Research, Tempe, Arizona
United States	Forte, Dana	Forte Family Practice/ CCT Research, Las Vegas, Nevada
United States	Fussell, Suzanne	Long Beach Clinical Trial Services Inc, Long Beach, California
United States	Gregerson, Gary	ASR, LLC, Nampa, Idaho
United States	Haffizulla, Jason	Precision Clinical Research, LLC, Sunrise, Florida
United States	Hassman, Michael	Hassman Research Institute, Berlin, New Jersey
United States	Hemmersmeier, John	South Ogden Family Medicine/ CCT Research, Ogden, Utah
United States	Hong, Mathew	M3 Wake Research, Inc, Raleigh, North Carolina
United States	Juvvadi, Nikhila	Affinity Health, Chicago, Illinois
United States	Latorre, Agustin	AppleMed Research Inc, Miami, Florida
United States	Martin, Earl	DM Clinical Research/Martin Diagnostic Clinic, Tomball, Texas
United States	Oppong, Yaa	Carolina Institute for Clinical Research, Fayetteville, North Carolina
United States	Patel, Suchet	Meridian Clinical Research, LLC, Endwell, New York
United States	Pickrell, Paul	Tekton Research, Austin, Texas
United States	Rosen, Jeffrey	AMR Miami, formerly Clinical Research of South Florida, Coral Gables, Florida

Country	Investigator	Institution
United States	Rothenberg, Joan	Velocity Clinical Research, Cleveland, Ohio
United States	Schwartz, Howard	Research Centers of America, Hollywood, Florida
United States	Seger, William	Benchmark Research, Fort Worth, Texas
United States	Tarakjian, Denis	WR-MCCR, LLC, San Diego, California
United States	Thakkar, Harish	Mt. Olympus Medical Research LLC, Sugarland, Texas
United States	Vanderzyl, John	Sugar Lakes Family Practice, PA - an Elligo Health Research Site, Sugarland, Texas
United States	Vrbicky, Keith	Meridian Clinical Research LLC, Norfolk, Nebraska
United States	Walters, Alton	Las Vegas Clinical Trials, North Las Vegas, Nevada
United States	Williams, Barton	Trial Management Associates, LLC, Wilmington, North Carolina
United States	Williams, Hayes	Achieve Clinical Research, LLC dba Accel Research Sites at Birmingham Clinical Research Unit, Birmingham, Alabama
United States	Wolf, Thomas	Methodist Physicians Clinic / CCT Research, Fremont, Nebraska
United States	Zeig, Steven	Elixia LLC, Palm Beach, Florida

6 *Supplementary Methods (Viral Sequencing)*


7 Sequencing of viral genomes from swabs was performed by Viroclinics-DDL (Netherlands).
8 Total nucleic acid (DNA/RNA) isolation was performed with the MagMAX™ Viral/Pathogen
9 Nucleic Acid Isolation kit on the KingFisher™ Flex instrument (ThermoFisher) using 400 µL
10 sample input. Nucleic acid elution was performed in 50 µL of elution buffer. Full-length
11 amplification of the target RNA, i.e., RNA encoding SARS-CoV-2 S, was performed by
12 amplifying 5 overlapping fragments of ~900 bp by nested RT-PCR using the primers sets from
13 the CDC Singleplex PCR 38 amplicons protocol (PacBio). The outer one-step RT-PCR reaction
14 was performed with the outer S-gene primer sets and the SuperScript™ III One-Step RT-PCR
15 System with Platinum™ Taq High Fidelity DNA Polymerase (ThermoFisher) using 5 µL of the
16 isolated RNA. The nested (inner) amplification step was performed with the inner primer sets
17 and the Phusion Hot Start II High-Fidelity DNA Polymerase (ThermoFisher) or Q5® Hot Start
18 High-Fidelity DNA Polymerase (NEB). Nested PCR products were analyzed by gel
19 electrophoresis using standard molecular biology protocols, to confirm successful
20 amplification.

21 Next-generation sequence (NGS) analysis of S-gene amplicons was performed using the MiSeq
22 or NextSeq Illumina platforms. NGS analysis was performed on samples consisting of two
23 pools of non-overlapping S-gene amplicons. To generate single datasets for reporting and
24 interpretation, the FASTQ files of the two pools of non-overlapping fragments were pooled
25 together *in silico*. After combining the two datasets, all data was mapped against the same
26 reference sequence (SARS-CoV-2 Wuhan-Hu-1 GenBank: MN908947.3). Identifying the
27 location on the reference genome allowed identification of reads that started or ended in or near
28 a primer region (possibly containing primer ambiguity), in order to select them for the primer
29 trimming algorithm. Sufficient nucleotides were trimmed off each read that was selected by this
30 process and the remaining part of the read was considered non-primer derived. For *in silico*
31 pooling and primer trimming, all primer locations were implemented in DDL's bioinformatics
32 ATHENA pipeline. The deep sequencing process comprised: quantification of S-gene amplicon
33 pools by PicoGreen or Qubit™; fragment dilutions and equimolar mixing to normalize the
34 concentrations of each of the amplicon pools; library preparation with the Nextera XT System
35 (Illumina); sequence reactions with 300-cycle kit (150 bp bidirectional reads) on the Illumina
36 Miseq or with a 300-cycle mid output kit on the Illumina Nextseq; Data QC and Data reporting.

37

38 *Supplementary Figure 1 | Circulating Variants During Course of Clinical Trial*
39 Each panel illustrates the variants circulating in time relative to the accrual of COVID-19
40 events for each nation in which the trial took place. Individual vertical columns indicate the
41 incidence rate of variants reported to GISAID during a seven-day period relative to the total
42 number of sequences reported for the period. Individual colors within the stacked columns
43 represent variants in circulation as a percentage of total, shown on the left Y axis. In cases
44 where sequence identity was not reported or does not refer to a Variant of Concern (VoC) or
45 Variant of Interest (VoI), the incidence was reported as undefined. Red lines indicate the
46 number of total adjudicated COVID-19 events contributing to the calculation of primary
47 vaccine efficacy accrued in each nation through time quantified relative to the right Y-axis. No
48 COVID-19 events accrued in Mexico. Dotted vertical lines indicate the date of first injection of
49 a participant by country. FPI: First Patient In.

50



51

52

53 *Supplementary Table S1 | Summary of demographics in the ITT set (NCT04636697)*

54 'N' is the number of participants in a population, while 'n' represents the number of
 55 participants in a category. Race or ethnic group was reported by the participants (who could
 56 have listed more than one category). SD: Standard deviation; Min.: Minimum; Max.: Maximum

	Healthy Adult		Older Adults (65+)		Adults with Comorbidities		All Participants	
	CoVLP + AS03	Placebo	CoVLP + AS03	Placebo	CoVLP + AS03	Placebo	CoVLP + AS03	Placebo
Participants (N)	10,816	10,835	62	65	1195	1166	12,074	12,066
Sex, n (%)								
Male	5,460 (50.5)	5,553 (51.3)	35 (56.5)	35 (53.8)	612 (51.2)	598 (51.3)	6,107 (50.6)	6,186 (51.3)
Female	5,356 (49.5)	5,282 (48.7)	27 (43.5)	30 (46.2)	583 (48.8)	568 (48.7)	5,966 (49.4)	5,880 (48.7)
Race, n (%)								
American Indian/ Alaska Native	27 (0.2)	23 (0.2)	0	0	3 (0.3)	7 (0.6)	30 (0.2)	30 (0.2)
Asian	137 (1.3)	137 (1.3)	1 (1.6)	0	11 (0.9)	10 (0.9)	149 (1.2)	147 (1.2)
Black/ African American	681 (6.3)	667 (6.2)	8 (12.9)	13 (20.0)	160 (13.4)	155 (13.3)	849 (7.0)	835 (6.9)
Multiple	197 (1.8)	237 (2.2)	1 (1.6)	0	26 (2.2)	26 (2.2)	224 (1.9)	263 (2.2)
Native Hawaiian or Other Pacific Islander	24 (0.2)	21 (0.2)	0	0	2 (0.2)	4 (0.3)	26 (0.2)	25 (0.2)
White or Caucasian	9,694 (89.6)	9,690 (89.4)	51 (82.3)	51 (78.5)	981 (82.1)	959 (82.2)	10,726 (88.8)	10,700 (88.7)
Other	1 (<0.1)	2 (<0.1)	0	0	0	0	1 (<0.1)	2 (<0.1)
Not Reported	52 (0.5)	54 (0.5)	0	1 (1.5)	10 (0.8)	5 (0.4)	62 (0.5)	60 (0.5)
Ethnicity, n (%)								
Hispanic or Latinx	8,965 (82.9)	8,955 (82.6)	15 (24.2)	26 (40.0)	915 (76.6)	915 (78.5)	9,895 (82.0)	9,896 (82.0)
Not Hispanic or Latinx	1,800 (16.6)	1,830 (16.9)	47 (75.8)	39 (60.0)	273 (22.8)	241 (20.7)	2,120 (17.6)	2,110 (17.5)
Not Reported/ Specified	51 (0.5)	50 (0.5)	0	0	7 (0.6)	10 (0.9)	58 (0.5)	60 (0.5)
Age at consent (years)								
Mean (SD)	32.0 (11.07)	31.9 (11.02)	69.9 (4.15)	69.5 (5.00)	38.8 (13.72)	39.2 (14.14)	32.8 (11.82)	32.8 (11.85)
Median	29.0	29.0	69.0	68.0	37.0	38.0	29.0	29.0
Min, Max	18, 64	18, 64	65, 80	65, 86	18, 82	18, 86	18, 82	18, 86

57 *Supplementary Table S2 | Baseline Comorbidities*

58 ‘N’ is the total number of participants who received a given vaccination. ‘n’ is the number of a
 59 participants who reported the specified comorbid condition and is shown as a percentage in
 60 brackets. Comorbidities reported for $\leq 0.1\%$ of the total population have not been included.

61

n (%)	CoVLP+AS03 N = 12036	Placebo N = 12040	Total N = 24076
Participants with at least one comorbidity	1781 (14.8)	1686 (14.0)	3467 (14.4)
Obesity	1246 (10.4)	1171 (9.7)	2417 (10.0)
Documented Hypertension	340 (2.8)	322 (2.8)	672 (2.8)
Type 2 Diabetes	116 (1.0)	100 (0.8)	216 (0.9)
Chronic Obstructive Lung disease (COPD)	41 (0.3)	45 (0.4)	86 (0.4)
Immunocompromised	48 (0.4)	40 (0.3)	88 (0.4)
Cardiovascular disease	40 (0.3)	41 (0.3)	81 (0.3)
Asthma	25 (0.2)	17 (0.1)	42 (0.2)

62 *Supplementary Table S3 | Efficacy by Subgroup (ITT)*

63 For most subgroups (1), values indicate the number of positive cases (total number of
 64 participants in the subgroup: percentage positivity). For variants (2), values indicate number of
 65 sequenced cases assigned to the variant (percent positive). Yrs indicate years, 95% CI indicates
 66 95% confidence interval. VE indicates Vaccine Efficacy and NA indicates not applicable.

Subgroup	Placebo	CoVLP+AS03	VE (95% CI)
All Participants	125 (12,067; 1.0%)	40 (12,074; 0.3%)	69.5 (56.7, 78.8)
Baseline Health, Age			
Healthy, ≥18 to <65 yrs	111 (10,835; 1.0%)	36 (10,0816; 0.3%)	68.9 (55.0, 78.9)
Healthy, ≥65 yrs	1 (65; 1.5%)	1 (62, 1.6%)	12.9 (-3,295.5, 97.8)
Significant comorbidities, ≥18 yrs	13 (1,166; 1.1%)	3 (1,195, 0.3%)	78.6 (30.2, 95.1)
Sex			
Male	58 (6,186; 0.9%)	22 (6,107, 0.4%)	63.5 (41.0, 78.1)
Female	67 (5,880; 1.1%)	18 (5,966, 0.3%)	74.5 (57.8, 85.2)
Race or Ethnic Group			
Asian	2 (147; 1.4%)	0 (149; 0%)	100.0 (-195.1, NA)
Black or African American	9 (835; 1.1%)	5 (849; 0.6%)	47.3 (-57.6, 84.0)
White or Caucasian	107 (10,700; 1.0%)	34 (10,726; 0.3%)	69.7 (55.7, 79.6)
Latinx or Hispanic	88 (9,896; 0.9%)	31 (9,895; 0.3%)	66.6 (50.1, 78.1)
Not Latinx or Hispanic	37 (2,110; 1.8%)	9 (2,120; 0.4%)	76.6 (52.8, 89.3)
Disease Severity			
Moderate	33 (12,067; 0.3%)	8 (12,074; <0.1%)	76.8 (51.4, 90.0)
Moderate/Severe	36 (12,067; 0.3%)	8 (12,074; <0.1%)	78.8 (55.8, 90.8)
Severe	3 (12,067; <0.1%)	0 (12,074; 0%)	100.0 (-63.7, NA)
Seropositivity at Baseline			
Seropositive	3 (1,791; 0.2%)	6 (1,776; 0.3%)	-94.3 (-852.1, 51.6)
Seronegative	121 (10,106; 1.2%)	33 (10,115; 0.3%)	74.0 (62.1, 82.5)
Variants			
Ancestral	0 (0%)	0 (0%)	NA
Alpha	6 (<0.1%)	0 (0%)	100 (38.2 NA)
Beta	0 (0%)	0 (0%)	NA
Gamma	47 (0.4%)	6 (<0.1%)	87.8 (73.0, 95.3)
Delta	44 (0.4%)	12 (<0.1%)	74.0 (51.7, 86.8)
Lambda	3 (<0.1%)	0 (0%)	100 (-63.7, NA)
Mu	4 (<0.1%)	0 (0%)	100.0 (-6.4, NA)
Omicron	0 (0%)	0 (0%)	NA

67

68 *Supplementary Table S4 / Incidence of Solicited Local Adverse Events (Safety Analysis Set)*

69 ‘N’ is the total number of participants in the Safety Analysis Set who received a given
 70 vaccination. ‘n’ is the number of a participants reporting at least 1 occurrence of the specified
 71 event category and is shown as a percentage in brackets. For each category, Grade 1 = Mild;
 72 Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially life threatening. If a participant
 73 had the same AE but with different grades over time, the highest grade was reported. ‘Missing’
 74 rows counted participants within the population if they did not have a non-missing assessment
 75 or had an assessment with a non-graded value.

n (%)	Vaccination 1		Vaccination 2		Overall	
	CoVLP+ AS03	Placebo	CoVLP+ AS03	Placebo	CoVLP+ AS03	Placebo
	N = 4 136	N = 3 683	N = 4 136	N = 3 683	N = 4 136	N = 3 683
At least 1 solicited local AE	3538 (85.5)	1149 (31.2)	3496 (84.5)	1135 (30.8)	3819 (92.3)	1677 (45.5)
Grade 1	3021 (73.0)	1123 (30.5)	2494 (60.3)	1111 (30.2)	2590 (62.6)	1629 (44.2)
Grade 2	484 (11.7)	24 (0.7)	917 (22.2)	23 (0.6)	1115 (27.0)	45 (1.2)
Grade 3	33 (0.8)	2 (<0.1)	85 (2.1)	1 (<0.1)	114 (2.8)	3 (<0.1)
Grade 4	0	0	0	0	0	0
Missing	4 (<0.1)	6 (0.2)	74 (1.8)	12 (0.3)	2 (<0.1)	5 (0.1)
Pain	3514 (85.0)	1 082 (29.4)	3 483 (84.2)	1 100 (29.9)	3 806 (92.0)	1 604 (43.6)
Grade 1	3 072 (74.3)	1 066 (28.9)	2 625 (63.5)	1 080 (29.3)	2 758 (66.7)	1 570 (42.6)
Grade 2	420 (10.2)	15 (0.4)	830 (20.1)	20 (0.5)	999 (24.2)	33 (0.9)
Grade 3	22 (0.5)	1 (<0.1)	28 (0.7)	0	49 (1.2)	1 (<0.1)
Grade 4	0	0	0	0	0	0
Missing	4 (<0.1)	6 (0.2)	74 (1.8)	12 (0.3)	2 (<0.1)	5 (0.1)
Redness	281 (6.8)	107 (2.9)	633 (15.3)	77 (2.1)	815 (19.7)	167 (4.5)
Grade 1	238 (5.8)	101 (2.7)	446 (10.8)	75 (2.0)	596 (14.4)	159 (4.3)
Grade 2	36 (0.9)	5 (0.1)	145 (3.5)	1 (<0.1)	172 (4.2)	6 (0.2)
Grade 3	7 (0.2)	1 (<0.1)	42 (1.0)	1 (<0.1)	47 (1.1)	2 (<0.1)
Grade 4	0	0	0	0	0	0
Missing	6 (0.1)	8 (0.2)	76 (1.8)	13 (0.4)	3 (<0.1)	5 (0.1)
Swelling	774 (18.7)	108 (2.9)	1241 (30.0)	113 (3.1)	1548 (37.4)	200 (5.4)
Grade 1	660 (16.0)	100 (2.7)	974 (23.5)	110 (3.0)	1211 (29.3)	189 (5.1)
Grade 2	102 (2.5)	7 (0.2)	240 (5.8)	3 (<0.1)	300 (7.3)	10 (0.3)
Grade 3	12 (0.3)	1 (<0.1)	27 (0.7)	0	37 (0.9)	1 (<0.1)
Grade 4	0	0	0	0	0	0
Missing	5 (0.1)	6 (0.2)	74 (1.8)	12 (0.3)	2 (<0.1)	5 (0.1)

76 *Supplementary Table S5 / Incidence of Solicited Systemic Adverse Events (Safety Analysis Set)*
77 'N' is the total number of participants in the Safety Analysis Set who received a given
78 vaccination. 'n' is the number of a participants reporting at least 1 occurrence of the specified
79 event category and is shown as a percentage in brackets. For each category, Grade 1 = Mild;
80 Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially life threatening. If a participant
81 had the same AE but with different grades over time, the highest grade was reported. 'Missing'
82 rows counted participants within the population if they did not have a non-missing assessment
83 or had an assessment with a non-graded value. Medically implausible fever temperature values
84 were excluded from table.

n (%)	Vaccination 1		Vaccination 2		Overall	
	CoVLP+ AS03 N = 4 136	Placebo N = 3 683	CoVLP+ AS03 N = 4 136	Placebo N = 3 683	CoVLP+ AS03 N = 4 136	Placebo N = 3 683
At least 1 solicited systemic AE	2835 (68.5)	2023 (54.9)	3190 (77.1)	1517 (41.2)	3612 (87.3)	2394 (65.0)
Grade 1	2017 (48.8)	1602 (43.5)	1388 (33.6)	1147 (31.1)	1538 (37.2)	1734 (47.1)
Grade 2	776 (18.8)	397 (10.8)	1671 (40.4)	349 (9.5)	1906 (46.1)	617 (16.8)
Grade 3	42 (1.0)	24 (0.7)	129 (3.1)	20 (0.5)	166 (4.0)	42 (1.1)
Grade 4	0	0	2 (<0.1)	1 (<0.1)	2 (<0.1)	1 (<0.1)
Missing	2 (<0.1)	6 (0.2)	72 (1.7)	12 (0.3)	2 (<0.1)	5 (0.1)
Chills	571 (13.8)	352 (9.6)	1 693 (40.9)	263 (7.1)	1 889 (45.7)	522 (14.2)
Grade 1	469 (11.3)	314 (8.5)	966 (23.4)	228 (6.2)	1 108 (26.8)	451 (12.2)
Grade 2	98 (2.4)	38 (1.0)	702 (17.0)	34 (0.9)	753 (18.2)	70 (1.9)
Grade 3	4 (<0.1)	0	24 (0.6)	1 (<0.1)	27 (0.7)	1 (<0.1)
Grade 4	0	0	1 (<0.1)	0	1 (<0.1)	0
Missing	8 (0.2)	9 (0.2)	74 (1.8)	12 (0.3)	2 (<0.1)	5 (0.1)
Fatigue	1 490 (36.0)	1 038 (28.2)	2 277 (55.1)	792 (21.5)	2 634 (63.7)	1 352 (36.7)
Grade 1	1 144 (27.7)	820 (22.3)	1 270 (30.7)	638 (17.3)	1 460 (35.3)	1 018 (27.6)
Grade 2	332 (8.0)	206 (5.6)	942 (22.8)	142 (3.9)	1 096 (26.5)	311 (8.4)
Grade 3	14 (0.3)	12 (0.3)	65 (1.6)	12 (0.3)	78 (1.9)	23 (0.6)
Grade 4	0	0	0	0	0	0
Missing	8 (0.2)	8 (0.2)	72 (1.7)	12 (0.3)	2 (<0.1)	5 (0.1)
Feeling of General Discomfort	1 200 (29.0)	699 (19.0)	2280 (55.1)	574 (15.6)	2 595 (62.7)	1002 (27.2)
Grade 1	907 (21.9)	582 (15.8)	1 154	459 (12.5)	1 341	784 (21.3)

n (%)	Vaccination 1		Vaccination 2		Overall	
	CoVLP+ AS03 N = 4 136	Placebo N = 3 683	CoVLP+ AS03 N = 4 136	Placebo N = 3 683	CoVLP+ AS03 N = 4 136	Placebo N = 3 683
Grade 2	278 (6.7)	111 (3.0)	(27.9) 1 089 (26.3)	109 (3.0)	(32.4) 1 203 (29.1)	207 (5.6)
Grade 3	15 (0.4)	6 (0.2)	36 (0.9)	6 (0.2)	50 (1.2)	11 (0.3)
Grade 4	0	0	1 (<0.1)	0	1 (<0.1)	0
Missing	8 (0.2)	9 (0.2)	74 (1.8)	13 (0.4)	2 (<0.1)	5 (0.1)
Feeling of Swelling in the Axilla (Armpit)	266 (6.4)	123 (3.3)	461 (11.1)	71 (1.9)	613 (14.8)	182 (4.9)
Grade 1	233 (5.6)	121 (3.3)	389 (9.4)	66 (1.8)	515 (12.5)	175 (4.8)
Grade 2	32 (0.8)	2 (<0.1)	70 (1.7)	5 (0.1)	95 (2.3)	7 (0.2)
Grade 3	1 (<0.1)	0	2 (<0.1)	0	3 (<0.1)	0
Grade 4	0	0	0	0	0	0
Missing	8 (0.2)	9 (0.2)	75 (1.8)	13 (0.4)	3 (<0.1)	5 (0.1)
Feeling of Swelling in the Neck	475 (11.5)	328 (8.9)	632 (15.3)	245 (6.7)	905 (21.9)	484 (13.1)
Grade 1	427 (10.3)	298 (8.1)	514 (12.4)	217 (5.9)	746 (18.0)	432 (11.7)
Grade 2	46 (1.1)	28 (0.8)	112 (2.7)	28 (0.8)	151 (3.7)	50 (1.4)
Grade 3	2 (<0.1)	2 (<0.1)	6 (0.1)	0	8 (0.2)	2 (<0.1)
Grade 4	0	0	0	0	0	0
Missing	8 (0.2)	9 (0.2)	75 (1.8)	13 (0.4)	3 (<0.1)	5 (0.1)
Fever	44 (1.1)	34 (0.9)	355 (8.6)	18 (0.5)	390 (9.4)	52 (1.4)
Grade 1	31 (0.7)	26 (0.7)	259 (6.3)	10 (0.3)	282 (6.8)	36 (1.0)
Grade 2	10 (0.2)	7 (0.2)	70 (1.7)	6 (0.2)	79 (1.9)	13 (0.4)
Grade 3	3 (<0.1)	1 (<0.1)	25 (0.6)	2 (<0.1)	28 (0.7)	3 (<0.1)
Grade 4	0	0	1 (<0.1)	0	1 (<0.1)	0
Missing	59 (1.4)	59 (1.6)	92 (2.2)	27 (0.7)	8 (0.2)	11 (0.3)
Headache	1 644 (39.7)	1 299 (35.3)	2 325 (56.2)	940 (25.5)	2 786 (67.4)	1 662 (45.1)
Grade 1	1 288 (31.1)	1 089 (29.6)	1 363 (33.0)	732 (19.9)	1 634 (39.5)	1 300 (35.3)
Grade 2	342 (8.3)	200 (5.4)	927 (22.4)	196 (5.3)	1 105 (26.7)	341 (9.3)
Grade 3	14 (0.3)	10 (0.3)	34 (0.8)	11 (0.3)	46 (1.1)	20 (0.5)
Grade 4	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)	1 (<0.1)
Missing	6 (0.1)	9 (0.2)	74 (1.8)	13 (0.4)	2 (<0.1)	5 (0.1)
Joint Aches	642 (15.5)	406 (11.0)	1 361 (32.9)	313 (8.5)	1 627 (39.3)	595 (16.2)
Grade 1	510 (12.3)	355 (9.6)	838 (20.3)	268 (7.3)	1 028 (24.9)	502 (13.6)
Grade 2	129 (3.1)	47 (1.3)	504 (12.2)	44 (1.2)	578 (14.0)	88 (2.4)
Grade 3	3 (<0.1)	4 (0.1)	19 (0.5)	1 (<0.1)	21 (0.5)	5 (0.1)
Grade 4	0	0	0	0	0	0

n (%)	Vaccination 1		Vaccination 2		Overall	
	CoVLP+ AS03 N = 4 136	Placebo N = 3 683	CoVLP+ AS03 N = 4 136	Placebo N = 3 683	CoVLP+ AS03 N = 4 136	Placebo N = 3 683
Missing	8 (0.2)	8 (0.2)	72 (1.7)	12 (0.3)	2 (<0.1)	5 (0.1)
Muscle Aches	1 768 (42.7)	771 (20.9)	2 273 (55.0)	617 (16.8)	2770 (67.0)	1 083 (29.4)
Grade 1	1 437 (34.7)	698 (19.0)	1 354 (32.7)	539 (14.6)	1 683 (40.7)	944 (25.6)
Grade 2	318 (7.7)	71 (1.9)	875 (21.2)	73 (2.0)	1 031 (24.9)	133 (3.6)
Grade 3	13 (0.3)	2 (<0.1)	43 (1.0)	5 (0.1)	55 (1.3)	6 (0.2)
Grade 4	0	0	1 (<0.1)	0	1 (<0.1)	0
Missing	7 (0.2)	8 (0.2)	72 (1.7)	12 (0.3)	2 (<0.1)	5 (0.1)

85

86 *Supplementary Table S6 / Overall Summary of Unsolicited Adverse Events Twenty-One Days*
87 *after Each Vaccine (Safety Analysis Set)*

88 ‘N’ is the total number of participants in the Safety Analysis Set who received a given
89 vaccination. ‘n’ is the number of a participants reporting at least 1 occurrence of the specified
90 event category and is shown as a percentage in brackets. Grade 3 = Severe. Abbreviations: AE,
91 adverse event; AESI, adverse event of special interest; CoVLP, coronavirus-like particle;
92 MAAE, medically attended adverse event; n, number of subjects in category; pIMDs, potential
93 immune-mediated diseases, SAE, serious adverse event; VAED, vaccine-associated enhanced
94 disease.

n (%)	Vaccination 1		Vaccination 2		Overall	
	CoVLP+ AS03 N= 12 036	Placebo N= 12 040	CoVLP+ AS03 N= 11 312	Placebo N= 10 775	CoVLP+ AS03 N= 12 036	Placebo N= 12040
Immediate Unsolicited AEs	19 (0.2)	19 (0.2)	4 (<0.1)	7 (<0.1)	23 (0.2)	26 (0.2)
Unsolicited AEs	1 722 (14.3)	1 647 (13.7)	1 424 (12.6)	1 132 (10.5)	2 735 (22.7)	2 451 (20.4)
≥ Grade 3	39 (0.3)	38 (0.3)	30 (0.3)	30 (0.3)	69 (0.6)	65 (0.5)
SAEs	13 (0.1)	9 (<0.1)	11 (<0.1)	8 (<0.1)	24 (0.2)	16 (0.1)
Related SAEs	0	0	0	0	0	0
MAAEs	287 (2.4)	276 (2.3)	242 (2.1)	230 (2.1)	509 (4.2)	490 (4.1)
Related MAAEs	28 (0.2)	21 (0.2)	20 (0.2)	22 (0.2)	48 (0.4)	43 (0.4)
AEs Leading to Study Withdrawal	1 (<0.1)	5 (<0.1)	0	2 (<0.1)	1 (<0.1)	7 (<0.1)
AESIs Reported by the Investigator	2 (<0.1)	0	2 (<0.1)	0	4 (<0.1)	0
AESIs Identified by Data analysis						
Potential VAED	0	0	0	0	0	0
Related Potential VAED	0	0	0	0	0	0
Related Anaphylactic Reactions	0	0	0	0	0	0
pIMDs	8 (<0.1)	5 (<0.1)	7 (<0.1)	3 (<0.1)	15 (0.1)	8 (<0.1)
Related pIMDs	1 (<0.1)	0	1 (<0.1)	1 (<0.1)	2 (<0.1)	1 (<0.1)
AEs Leading to Death	0	2 (<0.1)	0	2 (<0.1)	0	4 (<0.1)

95 *Supplementary Table S7 | Overall Summary of Unsolicited Adverse Events 43 to 201 Days after*
 96 *Second Vaccination (Safety Analysis Set)*

97 ‘N’ is the total number of participants in the Safety Analysis Set who received a given
 98 vaccination. ‘n’ is the number of a participants reporting at least 1 occurrence of the specified
 99 event category and is shown as a percentage in brackets. Grade 3 = Severe. Abbreviations: AE,
 100 adverse event; AESI, adverse event of special interest; CoVLP, coronavirus-like particle;
 101 MAAE, medically attended adverse event; n, number of subjects in category; pIMDs, potential
 102 immune-mediated diseases, SAE, serious adverse event; VAED, vaccine-associated enhanced
 103 disease.

n (%)	Vaccination 1		Vaccination 2		Overall	
	CoVLP+ AS03 N= 12 036	Placebo N= 12 040	CoVLP+ AS03 N= 11 312	Placebo N= 10 775	CoVLP+ AS03 N= 12 036	Placebo N= 12040
Unsolicited AEs ≥ Grade 3	1 (<0.1) 0	5 (<0.1) 1 (<0.1)	510 (4.5) 21 (0.2)	475 (4.4) 28 (0.3)	511 (4.2) 21 (0.2)	480 (4.0) 29 (0.2)
SAEs	0	2 (<0.1)	19 (0.2)	20 (0.2)	19 (0.2)	22 (0.2)
Related SAEs	0	0	0	1 (<0.1)	0	1 (<0.1)
MAAEs	1 (<0.1)	3 (<0.1)	199 (1.8)	197 (1.8)	200 (1.7)	200 (1.7)
Related MAAEs	0	0	2 (<0.1)	2 (<0.1)	2 (<0.1)	2 (<0.1)
AEs Leading to Study Withdrawal	1 (<0.1)	0	3 (<0.1)	5 (<0.1)	4 (<0.1)	5 (<0.1)
AESIs Reported by the Investigator	0	0	2 (<0.1)	0	2 (<0.1)	0
AESIs Identified by Data analysis						
Potential VAED	0	0	0	0	0	0
Related Potential VAED	0	0	0	0	0	0
Related Anaphylactic Reactions	0	0	0	0	0	0
pIMDs	0	0	6 (<0.1)	2 (<0.1)	6 (<0.1)	2 (<0.1)
Related pIMDs	0	0	0	0	0	0
AEs Leading to Death	0	0	4 (<0.1)	5 (<0.1)	4 (<0.1)	5 (<0.1)

104

105

106 *Supplementary Table S8 / Incidence of Unsolicited Adverse Events (Safety Analysis Set)*
 107 'N' is the total number of participants in the Safety Analysis Set who received a given
 108 vaccination. 'n' is the number of a participants reporting at least 1 occurrence of the specified
 109 event PT category and is shown as a percentage in brackets. All events PT reported in $\geq 1\%$ of
 110 subjects after receiving first and or second treatment in CoVLP+AS03 treatment group are
 111 listed. PT, preferred term.

n (%)	Vaccination 1		Vaccination 2		Overall	
	CoVLP+ AS03	Placebo	CoVLP+ AS03	Placebo	CoVLP+ AS03	Placebo
	N= 12 036	N= 12 040	N= 11 312	N= 10 775	N= 12 036	N= 12040
Subjects with at least 1 unsolicited AE	1 722 (14.3)	1 647 (13.7)	1 424 (12.6)	1 132 (10.5)	2 735 (22.7)	2 451 (20.4)
Influenza	43 (0.4)	61 (0.5)	110 (1.0)	88 (0.8)	152 (1.3)	149 (1.2)
Headache	268 (2.2)	268 (2.2)	165 (1.5)	165 (1.5)	410 (3.4)	405 (3.4)
Nasal congestion	115 (1.0)	131 (1.1)	111 (1.0)	110 (1.0)	215 (1.8)	223 (1.9)
Oropharyngeal pain	76 (0.6)	90 (0.7)	75 (0.7)	82 (0.8)	147 (1.2)	169 (1.4)
Cough	57 (0.5)	73 (0.6)	60 (0.5)	57 (0.5)	115 (1.0)	127 (1.1)
Diarrhea	61 (0.5)	61 (0.5)	72 (0.6)	54 (0.5)	129 (1.1)	110 (0.9)
Nausea	61 (0.5)	45 (0.4)	74 (0.7)	42 (0.4)	128 (1.1)	85 (0.7)
Myalgia	90 (0.7)	67 (0.6)	62 (0.5)	43 (0.4)	146 (1.2)	109 (0.9)

112 *Supplementary Table S9 | Incidence of Adverse Events of Special Interest based on Serious*
 113 *Adverse Events Reported after Vaccination with Other COVID-19 Vaccines (Safety Analysis*
 114 *Set)*

115 ‘N’ is the total number of participants in the Safety Analysis Set who received a given
 116 vaccination. ‘n’ is the number of a participants reporting at least 1 occurrence of the specified
 117 event category and is shown as a percentage in brackets.

n (%)	Vaccination 1		Vaccination 2		Overall	
	CoVLP+ AS03	Placebo	CoVLP+ AS03	Placebo	CoVLP+ AS03	Placebo
	N= 12 036	N= 12 040	N= 11 312	N= 10 775	N= 12 036	N= 12040
Acute respiratory distress syndrome	0	1 (<0.1)	0	0	0	1 (<0.1)
Arrhythmia	1 (<0.1)	1 (<0.1)	0	1 (<0.1)	1 (<0.1)	2 (<0.1)
Myocarditis	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)	1 (<0.1)
Pericarditis	0	0	0	0	0	0
Bell’s palsy	1 (<0.1)	0	1 (<0.1)	0	2 (<0.1)	0
Facial Paralysis	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)	1 (<0.1)
Deep vein thrombosis	0	0	1 (<0.1)	0	1 (<0.1)	0
Embolism	0	0	0	0	0	0
Cerebral venous sinus thrombosis	0	0	0	0	0	0
Thrombocytopenia	0	0	0	0	0	0
Disseminated intravascular coagulation	0	0	0	0	0	0
Guillain-Barré syndrome	0	0	0	0	0	0

118